Startups
GlpBio provides life science and pharmaceutical developers with 30,000+ specific inhibitors, agonists, bioactive compounds, and kits, focusing on signaling pathways and disease research. The global literature is widely cited, the quality control system is strict, and the technical support is perfect.
Overview
Location
United States, California, Montclair
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 1, 2022 | GLPBIO LAUNCHES A NEW THERAPEUTIC AGENT MCC950 SODIUM | LOS ANGELES, CALIFORNIA, UNITED STATES, November 1, 2022 /EINPresswire.com/ -- GlpBio, one of China's leading biotech companies, launches a new therapeutic agent MCC950 Sodium, which can be used in the treatment of autoimmune diseases and a... |
| Sep 15, 2022 | Using Cell counting Kit-8 to measure cellular proliferation | Figure 1:Diagrammatic representation of the detection of live bacteria via dehydrogenase activity using cell counting Kit-8. (CCK) CHINA, September 15, 2022 /EINPresswire.com/ -- Cell counting Kit-8 is also known as CCK-8 which is used to d... |
Reviews 0
FAQ about GlpBio
What has the press written about GlpBio?
Parsers VC has collected 3 articles mentioning GlpBio, among them “GLPBIO LAUNCHES A NEW THERAPEUTIC AGENT MCC950 SODIUM” (Nov 1, 2022) and “Using Cell counting Kit-8 to measure cellular proliferation” (Sep 15, 2022).
Is GlpBio still active?
Yes, GlpBio is active; its latest activity on Parsers VC dates from Dec 2, 2022.